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A simple and versatile method for microencapsulation
of anti-epileptic drugs for focal therapy of epilepsy
Yu Chen,a Zhilian Yue,a Simon E. Moulton,*ab Patricia Hayes,a Mark J. Cookcd and
Gordon G. Wallace*a
Nearly 30% of epilepsy cases cannot be adequately controlled with current medical treatments. The reasons for
this are still not well understood, but there is a significant body of evidence pointing to the blood–brain barrier.
Resective surgery can provide an alternative method of epilepsy control; however this treatment option is not
suitable for most epilepsy sufferers. Local drug delivery through micro-injection to or implantation into the brain
provides an innovative approach to bypass the blood–brain barrier for epilepsy treatment. In order to develop
effective local delivery systems for anti-epilepsy drug (AED), we have prepared a variety of core–shell micro-
capsules via electrojetting, where a more hydrophobic polymer shell acts as a physical barrier to control the rate
of drug release from the drug-loaded polymeric core. The resulting microcapsules demonstrate highly drug
encapsulation efficiency, narrow size distribution and uniform morphology. Moreover, the release rate of AED
can be modulated by controlling the morphologies of the core–shell microcapsules.
Introduction
Epilepsy is a long-term neurological disorder, affecting more
than 60 million people worldwide. It is characterised by recurrent
and unpredictable seizures, which can cause loss of consciousness,
falls and injury, psychosocial disability, and even mortality.
Medication provided via oral administration is the first approach
to epilepsy treatment, but controls only up to 70% of the cases,
whilst the rest of the patients remain incompletely responsive to
medication.1,2 The reasons for this are not yet fully understood,
but there is significant body of evidence pointing to the blood–brain
barrier (BBB).3 The BBB protects the brain from harmful blood–
borne substances and microorganisms by separating the brain
parenchyma from the circulating blood. Such self-protection also
poses an obstacle to drug delivery to the brain. Nearly 100% of
high molecular weight drugs and 498% of low molecular weight
drugs are excluded from the brain.4–6 For instance, a typical
dosage of an antiepilepsy drug (AED), such as lacosamide (used
in this study), is 400–500 mg per day7,8 by oral administration.
However, the actual amount of lacosamide arriving at the sites of
seizures is very limited due to the limited ability of the drug to cross
the BBB.3 Moreover, this high systemic dosage causes serious whole
body side-effects, such as rashes, nausea and weight changes.
For patients whose seizures cannot be controlled by medications,
surgery represents an alternative option, which can be provided only
to appropriately selected patients, where the seizure origin in the
brain can be localized. In addition, a comprehensive pre-surgical
assessment must be conducted in order to ensure the benefits of
the operation. Following surgical therapy, the patients still need to
take AEDs for a long time to prevent epilepsy relapse.9,10
To improve epilepsy control, local drug delivery through
micro-injection or implantation in the brain to bypass the BBB
may offer an innovative approach to improve the efficacy of
medication. This approach can significantly reduce the dosage
of AEDs, while concurrently minimising the side effects associated
with systemic administration of AEDs.11,12 In addition, compared
to surgical resection, direct injection or implantation would
significantly reduce potential brain damage.13
An ideal local drug delivery system should be biocompatible,
biodegradable and exhibit an optimal drug release profile pertaining
to the targeted application. It should also be amenable to fabrication
and large scale production. Poly(lactic-co-glycolic acid) (PLGA) has
been intensively studied for local drug delivery.14–16 In particular,
it has been explored in treating central nervous system disorders,
such as Alzheimer’s17,18 and Parkinson’s19,20 diseases, as well
as in treating brain injury,21 demonstrating excellent brain
biocompatibility. Lacosamide, the R-enantiomer of 2-acetamido-
N-benzyl-3-methoxypropionamide, is a novel antiepilepsy drug.
Based on the efficacy and therapeutic index observed in a range
of animal models of epilepsy at the National Institutes of Health
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(NIH) Anticonvulsant Screening Program, lacosamide warranted
further evaluation and was subsequently developed as an AED for
both oral and intravenous use. It suggests that lacosamide has a
dual action underlying its anticonvulsant and analgesic. It’s also
found that lacosamide selectively enhances slow inactivation of
voltage-gated sodium channels without affecting fast inactivation.22
In terms of material fabrication, electrojetting, such as electro-
spinning and electrospraying, has attracted tremendous interest-
ing in recent years.23–28 It is a low-cost and versatile technique for
uniform fabrication of polymer structures ranging from nano-
scale to microscale.29–31 However, only limited studies have been
undertaken on the electrojetted systems in terms of morphology,
drug loading efficiency and drug release characteristics.31,32
Moreover, to the best of our knowledge, no study has yet to be
reported on core–shell structured electrojetted systems.
Herein we report a novel electrojetting technique for fabrication
of core–shell microspheres and microfibers, where AED-laden
polymer cores are surrounded by drug-free polymer shells that
act as a barrier to regulate drug release characteristics. A variety of
core–shell PLGA/lacosamide microcapsules, including microflakes,
flattened microspheres, microspheres, microspheres–fibers, beaded
microfibers, and microfibers, have been developed with narrow size
distribution and uniform morphology. These systems demonstrated
high efficiency in drug encapsulation and sustained drug release
characteristics, which makes them promising candidates as
injectable microspheres and polymer implants for local drug
delivery for epilepsy control.
Materials and methods
Materials
Poly(D,L-lactic-co-glycolic acid) (PLGA) (Mw B 60 000 Da) with
various molar ratio of lactide to glycolide, including PLGA 75/25
(lactide/glycolide = 75/25) and PLGA 85/15 (lactide/glycolide =
85/15), were purchased from Purac, Singapore, and used as
received. Lacosamide, an anti-epilepsy drug, was provided by
UCB Pharma Pty Ltd. All the others chemicals and reagents
were purchased from Sigma-Aldrich.
Electrojetting (electrospinning and electrospraying)
A range of solutions of PLGA 75/25 and lacosamide were prepared as
the core solutions for electrojetting. In these solutions, the ratio of
polymer/drug (w/w) was kept constant at 10/1, while the polymer
concentration varied from 0.75 to 15 wt%. A range of drug-free PLGA
85/15 solutions were prepared as the shell solutions for electro-
jetting, with the polymer concentration ranging from 0.5 to 10 wt%.
Electrojetting (electrospinning and electrospraying, respectively)
was conducted at room temperature using an NANON-01A electro-
spinning system (MECC Co. Ltd, Japan). A coaxial spinneret with
0.2 mm core and 0.8 mm sheath nozzles were connected to the
core and shell solutions. The distance from the spinneret tip to
collector was maintained at 12 cm, and the applied voltage for
electrospinning and electrospraying was 21 kV and 10 kV,
respectively. The feed rate was 0.1 mL h1 for the core solutions
and 0.4 mL h1 for the shell solutions. Aluminium foil was used
to collect the fabricated core–shell microcapsules, and the sam-
ples were further dried in a vacuum oven at room temperature for
48 hours to remove any residual organic solvent.
Morphological and dimensional statistical analysis
The morphologies of the as-prepared microcapsules were examined
using a Field Emission Scanning Electron Microscope (FESEM,
JEOL JSM-7500FA). The samples were sputter-coated with 20 nm
gold to avoid charge accumulation. Dimensional statistical analysis
was conducted by analysis of the SEM micrographs using the
imaging software, Leica Application Suite. All data were expressed
as mean  standard deviation (SD).
Determination of drug encapsulation efficiency
An extraction method was used to determine the drug encapsulation
efficiencies of the as-fabricated core–shell microcapsules. Briefly, each
sample (1 cm  1 cm) was placed into 1 mL methanol for 12 hours,
after which the methanol was removed and replenished with 1 mL of
fresh methanol. This extraction procedure was repeated four times
with each methanol sample allowed to evaporate to leave residual
drug behind which was reconstituted using artificial cerebrospinal
fluid (aCSF, 0.866 wt% NaCl, 0.224 wt% KCl, 0.0164 wt% MgCl2
6H2O, and 0.02066H2O CaCl26H2O in 0.001 M Phosphate Buffer
Solution). Each aCSF sample was then analysed for drug content
using HPLC (see below). The 4th reconstituted sample showed
absence of drug indicating that the entire drug had been extracted
from the electrojetted sample.
HPLC analysis was conducted on an Agilent 1260 Infinity HPLC
system. The analytical column used was an Atlantiss T3 C18 column
(5 mm, 250 mm  4.60 mm). The mobile phase consisted of MilliQ
water, acetonitrile (HPLC grade) and methanol (HPLC grade)
(65 : 26.2 : 8.8, v/v/v). The mobile phase flow rate was 0.8 mL min1,
and the UV-vis detection wavelength was 210 nm.33 The amounts of
released drug were calculated according to a pre-established
calibration curve that was obtained by plotting the peak areas
against respective concentrations of a range of standard lacosamide
solutions prepared in aCSF.
In vitro drug release study
In vitro drug release was conducted in artificial cerebrospinal
fluid (aCSF). Each sample (1 cm  1 cm) was incubated in 1 mL
of aCSF at 37 1C in a shaking water bath. At appropriate time
intervals, the release medium was withdrawn and replaced with
1 mL of fresh aCSF. The released samples were stored at 20 1C
prior to the HPLC analysis for quantification of the amounts of
the lacosamide released.
Results and discussion
Preparation of various forms of electrojetted core–shell
microcapsules
Electrojetting, including electrospinning and electrospraying,
represents a simple and versatile method for producing mono-
disperse polymeric spheres and fibres at the nano- and micro-
scale.23,34 Electrojetting is governed by the interactions between
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the electrostatic repulsion induced by an applied electric field,
and surface tension of a liquid droplet. When the electrostatic
repulsion surpasses the surface tension to a critical point,
liquid ejection will occur at the surface of the droplet. The
liquid jet will undergo a whipping process, which leads to the
formation of either fibres (electrospinning, as shown in
Fig. 1a), or spheres (electrospraying, as shown in Fig. 1b) at
the nano- or micro-scale. Therefore, the final electrojetted
structure is determined by the electric force applied and the
properties of polymer solutions. The polymer solution properties
are governed by the molecular weight and concentration of the
polymer, as well as the solvent properties.
In this study, PLGA 75/25 and lacosamide were used as the core
structural materials, whilst PLGA 85/15, a more hydrophobic
copolymer, was used as the shell material.35 Chloroform was used
as the solvent, with a low boiling point of 61.2 1C. By adjusting the
applied voltage and screening of the concentrations of the core
and shell solutions, microcapsules with various shapes (Fig. 2),
including microflakes, flattened microspheres, microspheres,
microspheres–fibres, beaded microfibers, and microfibers, were
successfully fabricated. These microstructures, together with their
respective fabrication conditions, including the concentrations
of the core and shell solutions and voltage, are summarised in
Table 1. For electrospraying of microflakes, flattened micro-
spheres, microspheres or microspheres–fibers, a 10 kV voltage
was used, whereas for electrospinning of beaded microfibers or
microfibers, a 21 kV voltage was used.
Morphological and dimensional statistical analysis
During the electrojetting process for fabrication of the microflakes or
flattened microspheres, both the polymer concentrations in the core
Fig. 1 Schematic illustration of the electrojetting setup, including (a)
electrospinning of microfibers and (b) electrospraying of microspheres.
Fig. 2 Scanning electron microscope (SEM) images of various PLGA
microcapsules; (a and b) microflakes, (c and d) flattened microspheres,
(e and f) microspheres, (g and h) microspheres–fibers, (i and j) beaded
microfibers, (k and l) microfibers.
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and shell solutions are very low (Table 1). This results in the rapid
collapse of PLGA microcapsules during solvent evaporation and
polymer solidification, to produce the microflakes and flattened
microspheres with a rough, pitted and porous surface topography.36
At higher PLGA concentrations, such as 6 wt% for the core solution
and 4 wt% for the shell solution, microspheres are produced,
exhibiting a much smoother surface. Further increasing the PLGA
concentrations to 7.5 wt% for the core and 5 wt% for the shell results
in concurrent formation of microspheres and microfibers, where the
diameters of fibres are much thinner than those of the micro-
spheres. The portion of the microfibers in the microcapsules
increases with increasing the polymer concentrations. When the
polymer concentration reaches 15 wt% for the core and 10 wt% for
the shell, only microfibers are produced. Our work demonstrates a
critical role of both the polymer concentrations of the core and shell
solutions in controlling the shape and morphologies of the electro-
jetted core–shell microcapsules. A similar concentration effect has
recently been reported in a range of PLGA microcapsules that were
produced by electrojetting a single solution and thus do not possess
the core–shell structures.31
In order to evaluate the shape, size and size distribution of the
as-prepared microcapsules, a Leica Application Suite was used to
analyse the SEM images. The sizes of the microflakes, flattened
microspheres, microspheres, microspheres–fibers, beaded micro-
fibers, and microfibers are presented in Fig. 3a with schematic
representation shown in Fig. 3b and the size distribution of each
type of microcapsule is shown in Fig. 3c. Each type of the electro-
jetted core–shell microcapsules exhibits a narrow size distribution
and uniform morphology. With an increase in the PLGA
concentrations, the dimension of the respective microcapsules firstly
increased, and then decreased in the case of microfibers. The
diameters are 2.26  0.67 mm for the microflakes, 2.67  0.46 mm
for the flattened microspheres, 4.42 1.08 mm for the microspheres,
5.35  0.94 mm for the microspheres–fibres, 7.02  1.45 mm for
the beaded microfibers, and 1.11  0.43 mm for the microfibers,
respectively.
In accordance with Hartman’s study,37 the dimension of PLGA
microspheres formed using electrospraying is governed by the






where d is the droplet size, r is the density of solution, e0 is the
permittivity of vacuum, Q is the liquid flow rate, g is the surface
tension of solution in ambient air, and K is the liquid conductivity.
Increasing the polymer concentration leads to an increase in the
solution viscosity, and a reduction in the surface tension (g), and
consequently an increase in microsphere size (d) (eqn (1)).37 When
the polymer concentration becomes sufficiently high, the solution
can endure continuous and longer stretching from the nozzle tip
to the collector, which gives rise to much thinner microfibers
through a mechanism of electrospinning.
Drug encapsulation efficiency
It is shown in Table 1 that all the fabricated core–shell microcapsules
exhibit 490% drug loading efficiencies. The core–shell microfibers
demonstrate the highest drug loading efficiency (99.2  5.4%).
These encapsulation efficiencies are greater than those prepared
using other techniques, including emulsion, suspension, and
emulsion polymerization,38 solvent evaporation,38,39 spray drying,40
layer-by-layer.41 This can be ascribed to (i) the inherent core–shell
structures where drug is encapsulated in the core and further
protected by a shell of more hydrophobic polymer and (ii) the fast
solidification of the microcapsules at room temperature due to
the use of a low boiling point solvent, chloroform.31,42
In vitro drug release study
The representative in vitro release profiles of lacosamide from the
fabricated PLGA microflakes, microspheres, microspheres–fibers,
and microfibers are shown in Fig. 4. The sustained release
characteristics demonstrated by all the microcapsules could be
attributable to their core–shell structures, where the drug-free
polymer shells presents an additional barrier to the drug elution
from the core.35 The release profiles varied significantly with the
shape and morphologies of the microcapsules. The microflakes
exhibited the most rapid release characteristics, with 496% of the
encapsulated lacosamide being eluted within B43 hours. Within
the same period, the cumulative release of the lacosamide from
the microspheres, microspheres–fibres, and microfibers, was
approximately 75%, 60%, and 35% of the respective total
drug loading. Compared to the microflakes, microspheres, and
microsphere–fibers, microfibers exhibit significantly less initial
burst release.
It is also noted that there is no significant mass loss in the
microcapsules after the long-time incubation in aCSF (104 days),
other than that arising from the drug elution. This suggests minimal
polymer degradation of the electrojetted microcapsules taking place
within this period, which also indicates that the drug release from
these microcapsules is predominantly diffusion controlled. The
morphology and dimension of the PLGA microcapsules had a







voltage (kV) Type of microcapsule formed Drug loading (%)
S0w 0.75 0.5 10 Microflakes 90.6  5.2
S2w 3 2 10 Flattened microspheres 91.1  8.1
S4w 6 4 10 Microspheres 94.0  3.5
S5w 7.5 5 10 Microspheres–fibers 95.3  3.0
S8w 12 8 21 Beaded microfibers 94.9  4.2
S10w 15 10 21 Microfibers 99.2  5.4
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significant influence in the lacosamide release characteristics.
For the microcapsules dominant by a sphere/particulate shape,
including microflakes, microspheres, microspheres–fibers, the
release rate decreased with increasing the microcapsule dimension
(Fig. 3b and 4). With an increase in the sizes of the microcapsules,
the surface area to volume ratios of the microcapsules decrease,
and this leads to slower water penetration rates into the micro-
capsules and thus slower drug release profiles.
These microcapsules can serve as an injectable microparticulate
systems or polymer implants, for local pharmaceutical intervention
of epilepsy, as well as treatments in other neurological disorders,
such as Parkinson’s disease, Huntington’s disease and Alzheimer’s
disease. Compared to systemic administration that requires high
dosages, local implantation or injection using our drug-eluting
microcapsules can significantly reduce the dosage and side effects.
Moreover, our drug release study demonstrated that the daily
release dosage of our systems can be readily tailored by varying
the shape and size of the microcapsules.
Conclusions
In summary, a variety of core–shell structured PLGA micro-
capsules containing an anti-epilepsy drug, lacosamide, have
Fig. 4 Cumulative release of lacosamide from the fabricated PLGA
microcapsules in aCSF (pH 7.4) at 37 1C over 104 days (a). The release
profiles of the microcapsules in the first 20 days (b).
Fig. 3 Size of the fabricated microflakes (a), flattened microspheres,
microspheres, microspheres–fibers, beaded microfibers, and microfibers.
Schematically illustration of the detection points of the sizes of the
microcapsules (b). Size distribution of each type of microcapsule (c).
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been fabricated by a novel electrojetting technique. These
microcapsules, including microflakes, flattened microspheres,
microspheres, microspheres–fibers, beaded microfibers, and
microfibers, all demonstrated narrow size distribution and
uniform morphology, high efficiency of drug encapsulation
and sustained drug release characteristics. The release profile
of lacosamide varies with the morphologies and shape of the
core–shell microcapsules, and thus can be readily controlled
over long periods of time.
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